These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31347926)

  • 81. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
    Usiskin K; Kline I; Fung A; Mayer C; Meininger G
    Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open-label, active-controlled study.
    Tsurutani Y; Nakai K; Inoue K; Azuma K; Mukai S; Maruyama S; Iizuka T; Matsuzawa Y; Saito J; Omura M; Nishikawa T
    Diabetes Obes Metab; 2018 Nov; 20(11):2675-2679. PubMed ID: 29893003
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study.
    Inagaki N; Kondo K; Yoshinari T; Takahashi N; Susuta Y; Kuki H
    Expert Opin Pharmacother; 2014 Aug; 15(11):1501-15. PubMed ID: 25010793
    [TBL] [Abstract][Full Text] [Related]  

  • 84. A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes.
    Elmore LK; Baggett S; Kyle JA; Skelley JW
    Consult Pharm; 2014; 29(5):335-46. PubMed ID: 24849690
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study.
    Takeishi S; Tsuboi H; Takekoshi S
    Endocr J; 2017 Oct; 64(10):995-1005. PubMed ID: 28824042
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.
    Kadokura T; Zhang W; Krauwinkel W; Leeflang S; Keirns J; Taniuchi Y; Nakajo I; Smulders R
    Clin Pharmacokinet; 2014 Nov; 53(11):975-88. PubMed ID: 25316572
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study.
    Inagaki N; Kondo K; Yoshinari T; Maruyama N; Susuta Y; Kuki H
    Diabetes Obes Metab; 2013 Dec; 15(12):1136-45. PubMed ID: 23782594
    [TBL] [Abstract][Full Text] [Related]  

  • 88. A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin.
    Seino Y; Kaku K; Kadowaki T; Okamoto T; Sato A; Shirakawa M; O'Neill EA; Engel SS; Kaufman KD
    Diabetes Obes Metab; 2021 Jun; 23(6):1342-1350. PubMed ID: 33565686
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study.
    Shingaki T; Taki K; Koyanagi M; Nagaoka S; Yoshizawa K; Oki N; Yoshikawa A; Imaoka T
    Curr Med Res Opin; 2020 Jun; 36(6):947-958. PubMed ID: 32271092
    [No Abstract]   [Full Text] [Related]  

  • 90. Treatment satisfaction, safety, and effectiveness of biosimilar insulin glargine is comparable in patients with type 2 diabetes mellitus after switching from insulin glargine or insulin degludec: a post-marketing safety study.
    Taki K; Koyanagi M; Nagaoka S; Shingaki T
    Curr Med Res Opin; 2020 Dec; 36(12):1975-1983. PubMed ID: 33030354
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study.
    Kadokura T; Akiyama N; Kashiwagi A; Utsuno A; Kazuta K; Yoshida S; Nagase I; Smulders R; Kageyama S
    Diabetes Res Clin Pract; 2014 Oct; 106(1):50-6. PubMed ID: 25149596
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period.
    Araki E; Onishi Y; Asano M; Kim H; Ekholm E; Johnsson E; Yajima T
    J Diabetes Investig; 2016 Jul; 7(4):555-64. PubMed ID: 27181422
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin.
    Hayashi T; Murayama H; Shinfuku Y; Taniguchi T; Tsumiyama I; Oyama N
    Expert Opin Pharmacother; 2020 Jan; 21(1):121-130. PubMed ID: 31689132
    [No Abstract]   [Full Text] [Related]  

  • 95. Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.
    Iemitsu K; Kawata T; Iizuka T; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyanagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2017 Sep; 9(9):793-801. PubMed ID: 28811858
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus.
    Araki E; Tanizawa Y; Tanaka Y; Taniguchi A; Koiwai K; Kim G; Salsali A; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2015 Jul; 17(7):665-74. PubMed ID: 25772548
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance study.
    Kaku K; Yamamoto K; Fukushima Y; Mizuno S; Nitta D
    Expert Opin Drug Saf; 2022 Nov; 21(11):1411-1422. PubMed ID: 35379060
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Safety and effectiveness of dulaglutide 0.75 mg in Japanese patients with type 2 diabetes in real-world clinical practice: 36 month post-marketing observational study.
    Chin R; Nagaoka S; Nakasawa H; Tanaka Y; Inagaki N
    J Diabetes Investig; 2023 Feb; 14(2):247-258. PubMed ID: 36367417
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance study.
    Yabe D; Yamamoto F; Lund SS; Okamura T; Kadowaki T
    Expert Opin Drug Saf; 2022 Oct; 21(10):1303-1313. PubMed ID: 35418260
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study.
    Iemitsu K; Iizuka T; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Kawata T; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyagi S; Hoshino K; Ishikawa M; Obana M; Sasai N; Kaneshige H; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2016 May; 8(5):373-8. PubMed ID: 27081422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.